Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $63.07 in the prior trading day, Keros Therapeutics Inc (NASDAQ: KROS) closed at $60.35, down -4.31%. In other words, the price has decreased by -$4.31 from its previous closing price. On the day, 0.56 million shares were traded. KROS stock price reached its highest trading level at $63.51 during the session, while it also had its lowest trading level at $60.28.
Ratios:
Our goal is to gain a better understanding of KROS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 19.03 and its Current Ratio is at 19.03. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 13 ’24 when GORDON CARL L sold 250,000 shares for $44.01 per share. The transaction valued at 11,002,500 led to the insider holds 119,522 shares of the business.
ORBIMED ADVISORS LLC sold 250,000 shares of KROS for $11,002,500 on Aug 13 ’24. The Director now owns 119,522 shares after completing the transaction at $44.01 per share. On Aug 13 ’24, another insider, OrbiMed Genesis Master Fund, L, who serves as the Shareholder of the company, bought 29,400 shares for $44.84 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KROS now has a Market Capitalization of 2444621568 and an Enterprise Value of 1933224192. For the stock, the TTM Price-to-Sale (P/S) ratio is 3760.95 while its Price-to-Book (P/B) ratio in mrq is 4.45. Its current Enterprise Value per Revenue stands at 2969.622 whereas that against EBITDA is -9.528.
Stock Price History:
Over the past 52 weeks, KROS has reached a high of $73.00, while it has fallen to a 52-week low of $27.31. The 50-Day Moving Average of the stock is 1.73%, while the 200-Day Moving Average is calculated to be 8.90%.
Shares Statistics:
The stock has traded on average 352.75K shares per day over the past 3-months and 452710 shares per day over the last 10 days, according to various share statistics. A total of 40.51M shares are outstanding, with a floating share count of 32.22M. Insiders hold about 20.47% of the company’s shares, while institutions hold 75.87% stake in the company. Shares short for KROS as of 1730332800 were 2412173 with a Short Ratio of 6.84, compared to 1727654400 on 3017784. Therefore, it implies a Short% of Shares Outstanding of 2412173 and a Short% of Float of 8.1099994.
